Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.

The Prostate - 1 Jun 2021

Nizialek Emily, Lim Su Jin, Wang Hao, Isaacsson Velho Pedro, Yegnasubramanian Srinivasan, Antonarakis Emmanuel S

Abstract excerpt

BACKGROUND: Clinical outcomes may differ among patients presenting with primary (de novo) metastatic hormone-sensitive prostate cancer (mHSPC) versus secondary (metachronous) mHSPC occurring after local therapy. It is unknown what molecular features distinguish these potentially distinct presentations. METHODS: A single-center retrospective study of mHSPC patients classified as primary mHSPC (n = 121) or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Neoplasm Grading

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Neoplasms, Hormone-Dependent

Share to Neoplasms, Second Primary

Share to Progression-Free Survival

Share to Proportional Hazards Models

Share to Prostatic Neoplasms

Source

Identifiers

PMID: 33955569
DOI: 10.1002/pros.24135

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.PMID 33955569Read ↗

Impact of homologous recombination repair gene mutations on survival in metastatic prostate cancer: A real-world analysis from an observational database.Semantic proximity Read ↗

Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.Semantic proximity Read ↗

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.Semantic proximity Read ↗

Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.Semantic proximity Read ↗

Clinical implications of homologous recombination repair mutations in prostate cancer.Semantic proximity Read ↗

Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical ProstatectomySemantic proximity Read ↗

Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.Semantic proximity Read ↗

De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?Semantic proximity Read ↗

Genomics of lethal prostate cancer at diagnosis and castration resistanceSemantic proximity Read ↗

De Novo Metastatic Prostate Cancer: Are We Moving towards a Personalized Treatment?Semantic proximity Read ↗

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate CancerSemantic proximity Read ↗

Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.